Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 24 HOUR versus KOVANAZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 24 HOUR versus KOVANAZE.
CLARINEX D 24 HOUR vs KOVANAZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist with selective peripheral H1-receptor antagonist activity. Loratadine is a long-acting antihistamine that selectively antagonizes peripheral H1-receptors.
KOVANAZE (norepinephrine and phenylephrine) is a combination of two vasopressors: norepinephrine, an α1-adrenergic receptor agonist with β1-adrenergic activity, and phenylephrine, a selective α1-adrenergic receptor agonist. Both agents cause vasoconstriction and increase blood pressure via activation of α1-adrenergic receptors on vascular smooth muscle.
1 tablet (5 mg desloratadine/120 mg pseudoephedrine) orally once daily
Intravenous bolus of 1 mg/kg over 10 minutes, followed by intravenous infusion of 0.02 mg/kg/min for 4 hours, then 0.01 mg/kg/min for 20 hours.
None Documented
None Documented
Desloratadine: terminal t1/2 27 hours (range 20-50h) supporting once-daily dosing. Pseudoephedrine: t1/2 5-8 hours (up to 16h in alkaline urine).
Terminal elimination half-life: approximately 7-9 hours following nasal administration; clinical significance: supports twice-daily dosing regimen
Desloratadine: ~87% excreted as metabolites (41% urine, 43% feces), <2% unchanged. Pseudoephedrine: ~70-90% excreted unchanged in urine.
Renal excretion of unchanged drug: ~20-30%; fecal/biliary elimination: minimal (<5%); remainder as metabolites
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine + Corticosteroid Combination